Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM)

Proleukin(R) Observational Study to Evaluate the Treatment Patterns and Clinical Response in Malignancy (PROCLAIM(SM)) is the largest observational clinical database of high-dose interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients with renal cell carcino...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Joseph I., Wong, Michael K.K., Kaufman, Howard L., Daniels, Gregory A., Morse, Michael A., McDermott, David F., Agarwala, Sanjiv S., Lewis, Lionel D., Stewart, John H., Vaishampayan, Ulka, Curti, Brendan, Gonzalez, René, Lutzky, Jose, Rudraptna, Venkatesh, Cranmer, Lee D., Jeter, Joanne M., Hauke, Ralph J., Miletello, Gerald, Milhem, Mohammed M., Amin, Asim, Richart, John M., Fishman, Mayer, Hallmeyer, Sigrun, Patel, Sapna P., Van Veldhuizen, Peter, Agarwal, Neeraj, Taback, Bret, Treisman, Jonathan S., Ernstoff, Marc S., Perritt, Jessica C., Hua, Hong, Rao, Tharak B., Dutcher, Janice P., Aung, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875755/
https://www.ncbi.nlm.nih.gov/pubmed/27916626
http://dx.doi.org/10.1016/j.clgc.2016.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875755/
https://www.ncbi.nlm.nih.gov/pubmed/27916626
http://dx.doi.org/10.1016/j.clgc.2016.10.008

Ejemplares similares